KOLON LIFE SCIENCE Files Routine Corporate Group Status Disclosure: Financials and Ownership Details
KOLON LIFE SCIENCE is a listed company under the Kolon group. Market cap as of May 28, 2026 is approximately 684.6B KRW, with a stock price of 52,300 KRW.
As of end-2025, total assets were 906.4B KRW, total liabilities 323.7B KRW, and total equity 582.7B KRW, resulting in a debt ratio of 55.56%.
Full-year 2025 sales reached 205.5B KRW, operating profit 24.9B KRW, and net income 24.6B KRW, indicating solid profitability.
The largest shareholder is Kolon Corp. with a 24.76% stake. Lee Woong-yeol holds 16.45%, and related parties collectively hold 41.78%.
The company wholly owns its subsidiary Kolon Biotech. Among intercompany transactions, sales to Kolon Industries amounted to 66.9B KRW annually.
The board held 10 meetings from May 2025 to March 2026, approving key items such as MPPO technology transfer, bond issuance, and participation in subsidiary capital increases.
This disclosure is a routine corporate group status report with no immediate impact on shareholder value, such as new financing or dilution events.
[AI Comprehensive Analysis]This is a routine group status disclosure. While the company maintains stable cash and profitability, the absence of specific shareholder return policies or new business catalysts limits short-term stock price impact. Investors should monitor upcoming clinical results of drug pipelines or potential M&A for further momentum.
KOSDAQ Filing Information
Filing: Large Enterprise Group Status Disclosure [Annual And First Quarter Use (Individual Company)]